SYMVENU

This brand name is authorized in Singapore

Active ingredients

The drug SYMVENU contains one active pharmaceutical ingredient (API):

1 Cariprazine UNII KQD7C255YG - CARIPRAZINE HYDROCHLORIDE
Cariprazine is indicated for the treatment of schizophrenia in adult patients. The mechanism of action of cariprazine is not fully known. However the therapeutic effect of cariprazine may be mediated through a combination of partial agonist activity at dopamine D₃, D₂ (Ki values of 0.085-0.3 nM versus 0.49-0.71 nM respectively) and serotonin 5-HT_1A receptors (Ki values of 1.4-2.6 nM), and antagonist activity at serotonin 5-HT_2B, 5-HT_2A and histamine H₁ receptors (Ki values of 0.58-1.1 nM, 18.8 nM and 23.3 nM, respectively). Read about Cariprazine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SYMVENU Hard capsule	Health Sciences Authority (SG)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05AX15		N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics
Discover more medicines within N05AX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: SG	Health Sciences Authority	Identifier(s): 15743P, 15744P, 15745P, 15746P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.